A cycle generative adversarial network for improving the quality of four-dimensional cone-beam computed tomography images

一种用于提高四维锥束计算机断层扫描图像质量的循环生成对抗网络

阅读:2

Abstract

BACKGROUND: Four-dimensional cone-beam computed tomography (4D-CBCT) can visualize moving tumors, thus adaptive radiation therapy (ART) could be improved if 4D-CBCT were used. However, 4D-CBCT images suffer from severe imaging artifacts. The aim of this study is to investigate the use of synthetic 4D-CBCT (sCT) images created by a cycle generative adversarial network (CycleGAN) for ART for lung cancer. METHODS: Unpaired thoracic 4D-CBCT images and four-dimensional multislice computed tomography (4D-MSCT) images of 20 lung-cancer patients were used for training. High-quality sCT lung images generated by the CycleGAN model were tested on another 10 cases. The mean and mean absolute errors were calculated to assess changes in the computed tomography number. The structural similarity index measure (SSIM) and peak signal-to-noise ratio (PSNR) were used to compare the sCT and original 4D-CBCT images. Moreover, a volumetric modulation arc therapy plan with a dose of 48 Gy in four fractions was recalculated using the sCT images and compared with ideal dose distributions observed in 4D-MSCT images. RESULTS: The generated sCT images had fewer artifacts, and lung tumor regions were clearly observed in the sCT images. The mean and mean absolute errors were near 0 Hounsfield units in all organ regions. The SSIM and PSNR results were significantly improved in the sCT images by approximately 51% and 18%, respectively. Moreover, the results of gamma analysis were significantly improved; the pass rate reached over 90% in the doses recalculated using the sCT images. Moreover, each organ dose index of the sCT images agreed well with those of the 4D-MSCT images and were within approximately 5%. CONCLUSIONS: The proposed CycleGAN enhances the quality of 4D-CBCT images, making them comparable to 4D-MSCT images. Thus, clinical implementation of sCT-based ART for lung cancer is feasible.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。